Related Experiment Video
Updated: Aug 16, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Enoxaparin adherence for venous thromboembolism prophylaxis in hospitalized patients with sickle cell disease
Colleen Sakon1, Miley Nikirk1, Andrew Ross Wickman O'Brien2
1Pharmacy Department, Indiana University Health, Indianapolis, Indiana, USA.
Background:
Venous thromboembolism (VTE) is a common cause of morbidity and mortality in patients with sickle cell disease (SCD).
Methods:
This retrospective study assessed adherence to prescribed enoxaparin for VTE prophylaxis in adults with SCD while hospitalized. A total of 172 encounters of 72 unique patients were evaluated between 1 January and 31 December 2019. Patients were grouped based on adherence to prescribed enoxaparin. Group 1 received 100% of doses ordered. Group 2 received between 99% and 1% of doses ordered. Group 3 received 0% of doses ordered.
Results:
Only 45 encounters (32.3%) received 100% of ordered doses and 81 encounters (47%) did not receive any of the ordered enoxaparin doses. In total, only 37% of all prescribed enoxaparin doses were administered to patients.
Conclusion:
This low level of administered enoxaparin is concerning in a patient population at an increased risk for VTE. VTE prophylaxis adherence needs to be addressed with each admission and, if appropriate, alterative options to enoxaparin should be considered.
More Related Videos
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Endocarditis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism III: Nursing Management
Peripheral Artery Disease IV: Nursing Management

